^
    2d
    Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma (clinicaltrials.gov)
    P1/2, N=20, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P1/2 trial
    |
    cyclophosphamide • fludarabine IV
    4d
    Computational optimization of MALT1 inhibitors against DLBCL: a QSAR-guided molecular docking and dynamics study. (PubMed, In Silico Pharmacol)
    As this study is purely computational, experimental validation is required to confirm these findings. The online version contains supplementary material available at 10.1007/s40203-025-00466-7.
    Journal
    |
    MALT1 (MALT1 Paracaspase)
    8d
    NCI-2018-00315: Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, City of Hope Medical Center | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2025 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    CCND1 (Cyclin D1) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Chr t(11;14)
    |
    Imbruvica (ibrutinib) • pevonedistat (MLN4924)
    8d
    Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=35, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Jun 2026 --> Nov 2025 | Trial primary completion date: Jun 2026 --> Nov 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    CD19 positive
    |
    lenalidomide • Blincyto (blinatumomab)
    8d
    BGB-21447-101: A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies (clinicaltrials.gov)
    P1, N=112, Active, not recruiting, BeiGene | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    BGB-21447
    9d
    Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma (clinicaltrials.gov)
    P2, N=39, Active, not recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New P2 trial
    |
    Rituxan (rituximab) • Inokai (orelabrutinib)
    9d
    This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=42, Recruiting, LTZ Therapeutics, Inc. | Initiation date: Sep 2025 --> Dec 2025
    Trial initiation date
    13d
    Watch and Wait or Worry and Wait in Indolent Lymphoma (clinicaltrials.gov)
    P=N/A, N=250, Enrolling by invitation, Seoul National University Hospital | Not yet recruiting --> Enrolling by invitation | N=150 --> 250
    Enrollment open • Enrollment change
    14d
    Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=37, Recruiting, David Bond, MD | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    carboplatin • lenalidomide • cyclophosphamide • ifosfamide • etoposide IV • Monjuvi (tafasitamab-cxix)
    15d
    A Rare Case of Subglottic Malignant Lymphoma Requiring Emergency Tracheostomy. (PubMed, Cureus)
    As a further biopsy would have required general anesthesia and might still have yielded insufficient tissue for definitive subclassification, treatment was initiated for an unclassifiable low-grade B-cell lymphoma, with a plan to perform a repeat biopsy at recurrence for diagnostic confirmation. The patient subsequently received chemotherapy with bendamustine and rituximab and has sustained a complete response for seven years.
    Journal
    |
    CD5 (CD5 Molecule)
    |
    Rituxan (rituximab) • bendamustine
    15d
    Dominance of conjunctiva-associated lymphoid tissue in the feline ocular immune system, with identification of lacrimal duct-associated lymphoid tissue. (PubMed, J Vet Med Sci)
    In conclusion, CALT appears to contribute more significantly than LDALT to feline ocular immunity. Furthermore, given the pro-inflammatory nature of both CALT and CD3+CD20+ cells, our findings suggest that CALT is involved in the pathology of feline conjunctivitis.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1)
    15d
    Targeting paracaspase1 (MALT1) for cancer therapy: Updated progress and study on structure-activity relationships (SARs). (PubMed, Eur J Med Chem)
    This review provides an overview of the research progress and structure-activity relationships (SARs) of MALT1 inhibitors, including covalent inhibitors, allosteric inhibitors, PROTACs (Proteolysis-Targeting Chimeras), and activity-based probes. Additionally, it discusses the future opportunities and challenges in this field, aiming to provide insights for the future development of MALT1-targeted drugs.
    Review • Journal
    |
    MALT1 (MALT1 Paracaspase) • CASP1 (Caspase 1)